Anebulo Pharmaceuticals, Inc. ( (ANEB) ) has released its Q1 earnings. Here is a breakdown of the information Anebulo Pharmaceuticals, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, particularly in pediatric patients. In its recent earnings report, Anebulo highlighted the commencement of a Phase 1 clinical trial for an intravenous formulation of its lead drug candidate, selonabant, aimed at treating acute cannabis-induced toxicity in children. The company also received a significant grant from the National Institute on Drug Abuse to support this study. Financially, Anebulo reported operating expenses of $2.3 million and a net loss of $2.2 million for the first quarter of fiscal year 2026, with cash reserves of $10.4 million. Looking ahead, Anebulo is focused on advancing its selonabant IV formulation and exploring strategic alternatives, including a potential reverse stock split, as it aims to address the unmet need for treatments in cannabis toxicity, particularly in children.